Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
Status:
Completed
Trial end date:
2017-06-29
Target enrollment:
Participant gender:
Summary
This is a single-center, open label study. The primary aim of this project is to develop a
controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to
evaluate the capacity of vaccines, biologics (monoclonal antibodies, or mAbs), and drugs to
block malaria parasite transmission by assessing infectiousness of Plasmodium falciparum (Pf)
gametocyte carriers for Anopheles mosquitoes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Radboud University
Collaborators:
QIMR Berghofer Medical Research Institute The PATH Malaria Vaccine Initiative (MVI)
Treatments:
Atovaquone Atovaquone, proguanil drug combination Fanasil, pyrimethamine drug combination Piperaquine Proguanil Pyrimethamine Sulfadoxine